Yttrium-based therapy for neuroendocrine tumors

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmacology

Background:

• Peptide receptor radionuclide therapy (PRRT) utilizes radiolabeled peptides to target cancer cells.
• (90)Y-peptides represent a significant class of agents used in PRRT.
• Understanding the safety and efficacy profile of (90)Y-peptides is crucial for clinical application.

Purpose of the Study:

• To evaluate the tolerability and potential side effects of (90)Y-peptide therapy.
• To assess the impact of PRRT on target organs, specifically kidneys and bone marrow.
• To determine the relationship between administered radioactivity, organ toxicity, and therapeutic outcomes like tumor volume reduction.

Main Methods:

• Review of clinical data and patient outcomes following (90)Y-peptide administration.
• Analysis of acute and chronic side effects associated with PRRT.
• Dosimetric evaluation and correlation with observed toxicities and treatment efficacy.

Main Results:

• (90)Y-peptide therapy is generally well-tolerated with predominantly mild acute side effects.
• Chronic and permanent effects on kidneys and bone marrow are minimal when appropriate precautions are implemented.
• Tumor volume reduction can be achieved with adequate radiation doses, despite potential organ toxicity limits.

Conclusions:

• PRRT with (90)Y-peptides offers a generally safe and effective treatment option for certain cancers.
• Careful management of radioactivity dosage is essential to mitigate risks to critical organs.
• (90)Y-octreotide has been a widely utilized agent in the initial years of PRRT practice.